Verrica Pharmaceuticals’ CEO to Speak at TD Cowen Health Care Conference
West Chester, PA, February 25, 2025 – Verrica Pharmaceuticals Inc., a leading dermatology therapeutics company, has announced that Jayson Rieger, PhD, MBA, the President and Chief Executive Officer of Verrica, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston. This event, which brings together industry professionals, investors, and experts, will provide a platform for Dr. Rieger to discuss the latest developments at Verrica and its pipeline of potential dermatology treatments.
About Verrica Pharmaceuticals
Verrica Pharmaceuticals is a dermatology therapeutics company focused on developing medications for skin diseases requiring medical interventions. The company’s lead product candidate, VP-102, is a potential treatment for molluscum contagiosum, a viral infection that causes small, raised bumps on the skin. Verrica’s pipeline also includes VP-110, a topical treatment for warts, and VP-115, a potential treatment for plantar warts.
Impact on Individuals
For individuals living with molluscum contagiosum, Verrica’s progress in developing VP-102 could mean a new, effective treatment option. Molluscum contagiosum can be a persistent and embarrassing condition, and current treatments, such as topical creams, can be time-consuming and may not always be effective. Verrica’s participation in the TD Cowen Health Care Conference offers an opportunity to learn more about the potential benefits and availability of VP-102.
Impact on the World
The development of new treatments for skin diseases, such as Verrica’s pipeline of potential dermatology therapies, can have a significant impact on public health. According to the World Health Organization, common skin diseases, such as warts and molluscum contagiosum, affect millions of people worldwide, particularly children. Effective treatments for these conditions can help improve quality of life and prevent the spread of infection.
Conclusion
Verrica Pharmaceuticals’ participation in the TD Cowen 45th Annual Health Care Conference marks an exciting time for the company and its potential dermatology treatments. With a focus on developing medications for skin diseases requiring medical interventions, Verrica’s progress in the development of VP-102, VP-110, and VP-115 could bring new, effective treatment options to individuals living with conditions like molluscum contagiosum and warts. As the company continues to advance its pipeline, the potential impact on public health and the dermatology industry as a whole is significant.
- Verrica Pharmaceuticals to participate in TD Cowen Health Care Conference
- CEO Jayson Rieger to discuss company developments and pipeline
- Lead product candidate VP-102 a potential treatment for molluscum contagiosum
- Other pipeline products include VP-110 for warts and VP-115 for plantar warts
- New treatments for skin diseases can improve quality of life and prevent infection spread
